Product Images Oxaliplatin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Oxaliplatin NDC 0781-9315 by Sandoz Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

oxaliplatin novaplus 01

oxaliplatin novaplus 01

oxaliplatin novaplus 02

oxaliplatin novaplus 02

The text describes a graph displaying DFS probability over time in months for patients receiving two different treatments, FOLFOX4 and LVSFU2. The graph includes the number of events and patients at risk for each treatment arm, as well as the hazard ratio and stratified logrank test results. At 60 months, the DFS probability for FOLFOX4 is approximately 0.2 and for LVSFU2 is approximately 0.3. The hazard ratio of FOLFOX4 compared to LVSFU2 is 0.80 with a 95% confidence interval of 0.68 to 0.93. The stratified logrank test yielded a p-value of 0.003.*

oxaliplatin novaplus 03

oxaliplatin novaplus 03

This is a graph showing DFS Probability at different time points (in months) for a treatment arm (FOLFOX4) and a control arm (LV5FU2) in patients with Dukes C colorectal cancer. The Hazard Ratio for stage III patients is 0.78 with a 95% confidence interval of [0.65, 0.93], and the Logrank test has a p-value of 0.005.*

oxaliplatin novaplus 04

oxaliplatin novaplus 04

This is a chart showing the percentage of patients surviving and median survival months based on three different treatments: Oxaliplatin + 5-FU/LV, Irinotecan + 5-FU/LV, and Irinotecan + 5-FU/LV. The chart shows that the Oxaliplatin + 5-FU/LV treatment had the highest percentage of patients surviving and the longest median survival time. A statistical test was done comparing Oxaliplatin +5-FU/LV to Irinotecan + 5-FU/LV with significant results.*

oxaliplatin novaplus 05

oxaliplatin novaplus 05

The text contains information about Oxaliplatin, an injectable medication used as a cytotoxic agent. It is available in single-dose vials containing 50mg/10mL concentration. The medication should be protected from light and not frozen. The packaging includes a caution regarding its use, and it is available only by prescription.*

oxaliplatin novaplus 06

oxaliplatin novaplus 06

This appears to be a label for a medication called Oxaliplatin Injection, USP, which is administered intravenously. The medication comes in single-dose vials, with a concentration of 100mg/20ml. There are multiple NDC codes listed for different quantities of the medication. The label also includes the name of the manufacturer and a mention of a company called Novaplus.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.